Celiac.com Sponsor (A1):


Join eNewsletter


Celiac.com Sponsor (A1-m):



Join eNewsletter
  • Join Our Community!

    Ask us a question in our celiac / gluten-free forum.

  • Scott Adams

    Larazotide Acetate Improves Gluten-Related GI Symptoms in Celiacs

    Scott Adams
    0
    Reviewed and edited by a celiac disease expert.

      a systematic review and meta-analysis of data from all randomized controlled trials shows that Larazotide acetate (AT-1001) improves gluten-related GI symptoms in celiac patients.


    Healing Me. Image: CC BY 2.0--shannonkringen
    Caption: Healing Me. Image: CC BY 2.0--shannonkringen

    Celiac.com 09/29/2020 - Currently, the only medically accepted treatment for celiac disease is a completely gluten-free diet (GFD), which can be both expensive and challenging to maintain. One promising celiac treatment currently in development is larazotide acetate (AT-1001), an anti-zonulin, designed to regulate gut permeability in people with celiac disease. 

    A team of researchers recently conducted a systematic review and meta-analysis of data from all randomized controlled trials (RCTs) assessing the effectiveness and safety of larazotide acetate in celiac patients. 



    Celiac.com Sponsor (A12):






    Celiac.com Sponsor (A12-m):




    The research team included Ahmed Abu-Zaid, Noor Tariq Alhaddab, Razan Abdulkarim Alnujaidi, Hadeel Abdulaziz Alharbi, Fulwah Alangri, Naseem Alyahyawi, Aminah Kamal, Abdulaziz Khalaf Altowairqi, Habeeb Alhabeeb, Sami Almustanyir, and Reem Abdullah Alyoubi.

    They are variously affiliated with the College of Medicine at Alfaisal University in Riyadh, Saudi Arabia; the Department of Pediatrics at King Abdulaziz University Hospital, Jeddah, Saudi Arabia; the Department of Medicine at the Ministry of Health in Riyadh, Saudi Arabia; the Department of Medicine at the Alhada Armed Forces Hospital in Taif, Saudi Arabia; and the Research Center at King Fahad Medical City in Riyadh, Saudi Arabia.

    The team began by searching four databases from inception to 20-August-2020 using related keywords to isolate appropriate studies of larazotide acetate in people with celiac disease. The team identified all relevant RCTs and assessed bias risk. They then pooled continuous outcomes as mean difference and dichotomous outcomes as risk ratio with 95% confidence interval under fixed-effects meta-analysis model. 

    They found four RCTs that met the study parameters, which included 465 celiac patients on larazotide acetate, and 161 on a placebo. Three and two studies included data on the results for patients on gluten challenge and GFD, respectively. The total effect estimates showed no substantial difference in lactulose-to-mannitol ratio between larazotide acetate and placebo groups. 

    Analysis showed that larazotide acetate resulted in a significant improvement in symptoms in the gluten challenge, but not in the gluten-free subjects. The larazotide acetate group reported a favorable change in celiac-disease gastrointestinal symptom rating scale (celiac disease-GSRS) in the gluten challenge patients, compared with the gluten-free patients. 

    Compared to the placebo, larazotide acetate reduced incidents of "adverse event" (AE) gluten-related diarrhea in gluten challenge patients, while other AEs remained similar among the treatment groups. 

    From their data, the study team concludes that larazotide acetate is well-tolerated in patients, and better than a placebo at relieving celiac-related gastrointestinal symptoms.

    This article has not been peer reviewed. It reports new, un-evaluated, medical research, and should not be used to guide clinical practice. Read more about using larazotide acetate to treat celiac disease at Merxiv.org.

    Edited by Scott Adams

    0

    User Feedback

    Recommended Comments

    There are no comments to display.



    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Restore formatting

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • About Me

    Scott Adams was diagnosed with celiac disease in 1994, and, due to the nearly total lack of information available at that time, was forced to become an expert on the disease in order to recover. In 1995 he launched the site that later became Celiac.com to help as many people as possible with celiac disease get diagnosed so they can begin to live happy, healthy gluten-free lives.  He is co-author of the book Cereal Killers, and founder and publisher of the (formerly paper) newsletter Journal of Gluten Sensitivity. In 1998 he founded The Gluten-Free Mall which he sold in 2014. Celiac.com does not sell any products, and is 100% advertiser supported.


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-m):




  • Related Articles

    Jefferson Adams
    Celiac.com 05/27/2008 - People with celiac disease know all too well that the only effective treatment at present is faithfully following a gluten-free diet. There’s been a lot of talk about various therapies and enzyme treatments that would allow people with celiac disease to return to a normal diet. Talk to anyone who suffers from celiac disease and they’ll likely have a personal horror story about a time when they had an unhappy episode of cross-contamination.
    So, the idea of a drug that would prevent such symptoms is appealing, and the goal, desirable. The chief cause of recurring symptoms in celiac disease is accidental gluten exposure, usually thr...

    Jefferson Adams
    Celiac.com 02/04/2013 - Ever wonder what happens to all those celiac disease patients who volunteer to do a gluten-challenge in the name of science? Well, the short answer is that they likely suffer, and may incur gut damage, at least in the short term.
    A team of researchers looking for ways to reduce or eliminate that problem recently conducted a study using larazotide acetate, a first-in-class oral peptide that prevents tight junction opening, and may reduce gluten uptake and associated problems.
    The research team included C. P. Kelly, P. H. R. Green, J. A. Murray, A. DiMarino, A. Colatrella, D. A. Leffler, T. Alexander, R. Arsenescu, F. Leon...

    Jefferson Adams
    Celiac.com 12/20/2018 - Intestinal permeability is thought to play a key role in the translocation of bacteria that lead to nonalcoholic fatty liver disease (NAFLD), a disorder in which fat accumulates in the liver. Intestinal permeability is also thought to play a significant role in the development of Nonalcoholic steatohepatitis (NASH).
    In a new preclinical study, a team of researchers affiliated with Innovate Biopharmaceuticals recently assessed the effects of larazotide acetate on intestinal permeability. Their data from that study show that larazotide has a marked effect on intestinal permeability. 
    The company expects to see more ...

    Daniel Cojanu
    Celiac.com 01/25/2020 - Depending on what source you read, there may be as many as 6.5 million celiac patients in the U.S.  With these numbers, I have long believed that we really need to either find a cure or an effective way to manage this disease.  I, like many others, have been wondering if a "magic pill" would ever be produced so I could escape from the dry, terrible tasting, overpriced gluten-free food.  
    Thus, when I read an article about some research being done on celiac disease, I contacted the company conducting the clinical trials so I could be placed on their mailing list and hear about the results as soon as possible.  At the time, I ...